News this morning:
Cytoclonal Announces Patent Claim Approval for Lung Cancer Monoclonal Antibody
BusinessWire, Tuesday, April 04, 2000 at 10:09
DALLAS--(BUSINESS WIRE)--April 4, 2000--Cytoclonal Pharmaceutics
Inc. (NASDAQ:CYPH, CYPHZ), announced today that it has received
patent claim allowance by the U.S. Patent Office for its monoclonal
antibody LCG-Mab which recognizes a protein on the surface of
non-small cell lung cancer. Non-small lung cancer makes up about 65%
of lung cancer. The LCG-Mab is in development for a diagnostic test
and treatment of non-small cell lung cancer.
The monoclonal antibody recognizes a unique protein on the surface
of the lung cancer cell based on animal model studies and Phase I
human clinical studies. Separate patents have been issued to
Cytoclonal for the surface protein and the gene which codes for the
protein, U.S. Patents No. 5,773,579 and No. 5,589,579.
"Development of a diagnostic test for lung cancer similar to the
PSA test for prostate cancer would be a major advance for early
detection of the most common form of lung cancer," stated Dr. Arthur
P. Bollon, Chairman and Chief Executive Officer. "Patents on this
monoclonal antibody, the gene and the protein, give Cytoclonal a very
strong proprietary position, which is necessary for any potential
commercialization."
The LCG-Mab potentially could serve as a delivery system for drugs
such as Taxol(R). Cytoclonal is in discussion with potential partners
for development of the LCG-Mab for therapeutic use. Development of an
in vitro diagnostic test for non-small cell lung cancer is being
undertaken by Cytoclonal.
Cytoclonal Pharmaceutics is a biopharmaceutical company
specializing in the development of therapeutic and diagnostic products
for the treatment and prevention of cancer and infectious diseases.
Based in Dallas, Texas, the Company's lead programs involve paclitaxel
(active ingredient in Taxol(R)) production using fermentation and
genetic engineering in agreements with Bristol-Myers Squibb, the
treatment of Polycystic Kidney Disease using paclitaxel, Quantum Core
Technology(TM), the Company's proprietary rational drug design
targeting the human genome and OASIS(TM) optimized antisense library
for regulating genes. Other programs involve the discovery of human
genes through Retroselection(TM) with a focus on lung cancer, breast
cancer treatment by peptide inhibition of estrogen receptors and the
"immortality enzyme" telomerase. Additional information on Cytoclonal
can be found on the Company's website at www.cytoclonal.com.
Except for historical information, the matters discussed in this
news release may be considered "forward looking" statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
section 21E of the Securities Exchange Act of 1934, as amended. Such
statements include declarations regarding the intent, belief or
current expectations of the Company and its management. Prospective
investors are cautioned that any such forward-looking statements are
not guarantees of future performance and involve a number of risks and
uncertainties that could materially affect actual results.
CONTACT: Cytoclonal Pharmaceutics Inc., Dallas
Dr. Arthur P. Bollon, Chairman and CEO
214/353-2922
or
Porter, LeVay & Rose, Inc., New York
L. B. Stauffer, Sr. VP
Elisa Keys, VP-Media Relations
212/564-4700
KEYWORD: TEXAS
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL PHARMACEUTICAL
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com |
